Skyrizi Approved for Psoriatic Arthritis
Approval based on two Phase 3 trials showing more than 50 percent of patients receiving Skyrizi achieved ACR20 response at 24 weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.